AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (“Mirna”) announced today that the Company will moderate a session on the role and promise of microRNAs (miRNAs) in cancer during the Biotechnology Industry Organization (BIO) International Convention, which will be held June 27-30, 2011, in Washington DC.
“Every year, BIO’s International Convention attracts thousands of senior pharmaceutical and biotechnology executives, scientists, business development representatives, and regulators from all over the world, to create a global platform not only to discuss the state of the industry and potential business deals, but also to be educated on new and exciting developments in research, drug discovery and development. Although the science of miRNAs is still relatively young, they do represent promise as a new class of targeted cancer therapeutics, and I am therefore pleased for Mirna to be moderating a session on miRNAs, entitled “The Promise of miRNA-based Therapeutics in Cancer,” said Paul Lammers, M.D., President and Chief Executive Officer of Mirna Therapeutics.
The session on miRNAs on cancer will be held in the afternoon on Wednesday, June 29th, and will feature four distinguished scientists and researchers in the field:
- George Calin, M.D., Associate Professor, Department of Experimental Therapeutics, MD Anderson Cancer Center;
- Frank Slack, Ph.D., Professor of Molecular Biology, Department of Molecular, Cellular and Developmental Biology, Yale University
- David Brown, Ph.D., Director of Research, Mirna Therapeutics
- Eric Marcusson, Ph.D., Director of Drug Discovery, Regulus Therapeutics
The objectives of the session will be to present and discuss the role of microRNAs in the development and dissemination of cancer, the promise of miRNA-based diagnostics, and provide an update on the status of the development efforts of miRNA-based therapeutics.
About Mirna Therapeutics
Mirna Therapeutics is a biotechnology company focused on the development and commercialization of microRNA (miRNA) therapeutics. The Company has a substantial body of pending intellectual property around miRNAs developed by its own scientists as well as in-licensed from other institutions. Mirna’s IP portfolio contains >300 miRNAs with applications in oncology and other diseases. Oncology-directed miRNAs include those that are key tumor suppressors in cancer, such as miR-34 and let-7 that have proven to block tumor growth in a number of different pre-clinical animal studies. The Company, founded in 2007, is located in Austin, Texas. For more information, visit www.mirnarx.com.
Mirna Therapeutics, Inc.
Paul Lammers, M.D., M.Sc., 512-901-0900
KEYWORDS: United States North America District of Columbia Texas
INDUSTRY KEYWORDS: Surgery Health Biotechnology Clinical Trials Hospitals Medical Devices Oncology Pharmaceutical Radiology Other Health Managed Care